⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3807990 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5693282 | 0.99 | — | — | |
| Hydrochloric Acid SCHEMBL3056954 | 0.99 | — | — | |
| SCHEMBL13576269 | 0.79 | CFD (0.30) | — | |
| SCHEMBL1160743 | 0.79 | CFD (0.30) | — | |
| SCHEMBL8002948 | 0.79 | CFD (0.30) | — | |
| SCHEMBL635489 | 0.79 | CFD (0.30) | — | |
| SCHEMBL669441 | 0.79 | CFD (0.30) | — | |
| SCHEMBL13646921 | 0.79 | CFD (0.30) | — | |
| Hydrochloric Acid SCHEMBL1536296 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| US-8710229-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130267713-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-10 | — | — | US | disclosed |
| US-8507722-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2111396-B1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | JANSSEN R & D IRELAND (IE) | 2013-08-07 | — | — | EP | disclosed |
| US-6995174-B2 | for inhibiting proteases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050090432-A1 | Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-28 | — | — | US | disclosed |
| US-6872805-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1505963-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004094452-A2 | MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1337550-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002060926-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |